AveXis, Inc. (AVXS) Given a $103.00 Price Target at Chardan Capital
AveXis, Inc. (NASDAQ:AVXS) has been given a $103.00 target price by Chardan Capital in a report released on Sunday. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s target price points to a potential upside of 45.32% from the stock’s current price.
A number of other analysts have also weighed in on the company. BMO Capital Markets restated an “outperform” rating and issued a $95.00 target price on shares of AveXis in a research note on Friday. Citigroup Inc. set a $100.00 target price on AveXis and gave the company a “buy” rating in a research note on Thursday. Jefferies Group LLC restated a “buy” rating and issued a $92.00 target price on shares of AveXis in a research note on Thursday, May 25th. Finally, Goldman Sachs Group, Inc. (The) raised their target price on AveXis from $91.00 to $108.00 and gave the company a “buy” rating in a research note on Friday, March 17th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $87.86.
AveXis (AVXS) traded up 2.166% during trading on Friday, hitting $72.415. 249,513 shares of the stock traded hands. AveXis has a one year low of $31.55 and a one year high of $85.98. The stock’s market cap is $2.01 billion. The company has a 50-day moving average price of $74.51 and a 200 day moving average price of $65.13.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, May 11th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.13. During the same quarter in the prior year, the company earned ($1.24) earnings per share. Analysts expect that AveXis will post ($4.41) earnings per share for the current year.
In related news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $81.39, for a total value of $144,874.20. Following the completion of the sale, the vice president now directly owns 1,780 shares in the company, valued at $144,874.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 5,341 shares of company stock valued at $406,682.
Hedge funds have recently made changes to their positions in the company. VHCP Management II LLC purchased a new stake in shares of AveXis during the first quarter worth approximately $24,501,000. Geode Capital Management LLC purchased a new stake in shares of AveXis during the first quarter worth approximately $1,490,000. Goldman Sachs Group Inc. purchased a new stake in shares of AveXis during the first quarter worth approximately $1,795,000. Pictet Asset Management Ltd. purchased a new stake in shares of AveXis during the first quarter worth approximately $536,000. Finally, State Street Corp purchased a new stake in shares of AveXis during the first quarter worth approximately $1,058,000. Hedge funds and other institutional investors own 90.47% of the company’s stock.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.